ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In 2001, the identification of imatinib (Gleevec) as a small molecule ATP-pocket inhibitor of BCR-ABL dramatically re-defined the treatment of CML and had a major impact on the survival of patients with CML [81,82,83].